Celyad Oncology SA (FRA:1C0)

Market Cap	11.68M -34.8%
Revenue (ttm)	21.00K -88.7%
Net Income	830.00K
EPS	0.02
Shares Out	n/a
PE Ratio	14.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.2210
Previous Close	0.2170
Day's Range	0.2210 - 0.2210
52-Week Range	0.1285 - 0.4550
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1C0

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error